Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Antibiotic Infusion In Children
NCT07575009Phase 3Recruiting
- Sponsor
- Tampere University Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of benzylpenicillin, cloxacillin, piperacillin + tazobactam and vancomycin in bacterial infection, sponsored by Tampere University Hospital. Primary endpoints: Cost of treatment, Duration of fever and 7 more. Started Apr 2026; status: recruiting.
02
Drugs
benzylpenicillincloxacillinpiperacillin + tazobactamvancomycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT07575009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07575009.